Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Use of LCAT to Reduce Cholesterol and Prevent Atherosclerosis

Posted Jun 15 2010 5:00pm

Description of Invention:
Available for licensing and commercial development is a method of decreasing accumulation of cholesterol in arteries of humans by administering lecithin-cholesterol acyltransferase (LCAT). This method is useful for the therapeutic treatment of subjects at risk for developing atherosclerosis.

High plasma concentration of HDL cholesterol is associated with reduced risk of cardiovascular diseases (such as ischemic stroke and myocardial infarction). In contrast, low levels of HDL are associated with increased risk of atherosclerotic diseases. The plasma protein enzyme LCAT plays a critical role in the metabolism of HDL and it facilitates the removal of cholesterol from the body. Individuals with a mutation in the LCAT gene have low HDL plasma levels and exhibit an increased risk for atherosclerosis.

Therefore, upregulation of LCAT function has been proposed as an HDL-C increasing therapy, and may have atheroprotective effects. This invention provides for several methods of administering LCAT polypeptide to decrease cholesterol accumulation in arteries.

Development Status:
Animal data available.

Inventors:
Silvia Santamarina-fojo (NHLBI)
Jeffrey M Hoeg (NHLBI)
H. Bryan Brewer (NHLBI)


Patent Status:
HHS, Reference No. E-007-1996/0
PCT, Application No. PCT/US96/18159 filed 08 Nov 1996
US, , Patent No. 6,635,614, Issued 21 Oct 2003
AU, , Patent No. 728257, Issued 19 Apr 2001
HHS, Reference No. E-007-1996/0


Relevant Publication:
  1. JM Hoeg et al. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Natl Acad Sci USA. 1996 Oct 15;93(21):11448-11453. [ PubMed abs ]


Licensing Status:
Available for non-exclusive or exclusive licensing.


Portfolios:
Internal Medicine
Internal Medicine - Therapeutics
In-vivo Data



For Additional Information Please Contact:
Fatima Sayyid MHPM
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325 Room 21,
Rockville, MD 20852
United States
Email: Fatima.Sayyid@nih.hhs.gov
Phone: 301-435-4521
Fax: 301-402-0220


Ref No: 1448

Updated: 06/2010

Post a comment
Write a comment:

Related Searches